Insulin resistance and cardiovascular disease

CE Kosmas, MD Bousvarou… - Journal of …, 2023 - journals.sagepub.com
Insulin resistance (IR) and cardiovascular disease (CVD) represent two universal public
health hazards, especially in today's Western societies. A causal-effect relationship has …

[HTML][HTML] Insights into pathogenesis, nutritional and drug approach in sarcopenia: a systematic review

RH Mellen, OS Girotto, EB Marques, LF Laurindo… - Biomedicines, 2023 - mdpi.com
Sarcopenia is a multifactorial condition related to the loss of muscle mass and strength due
to aging, eating habits, physical inactivity, or even caused by another disease. Affected …

Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives

F Ferrari, A Moretti, RF Villa - Pharmacology & therapeutics, 2022 - Elsevier
Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases

D Cheng, S Yang, X Zhao, G Wang - Drug design, development …, 2023 - Taylor & Francis
Recent clinical guidelines have emphasized the importance of screening for cognitive
impairment in older adults with diabetes, however, there is still a lack of understanding about …

[HTML][HTML] Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

B Vergès, V Aboyans, D Angoulvant… - Cardiovascular …, 2022 - Springer
Several randomized controlled trials have demonstrated the benefits of glucagon-like
peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this …

Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia

S Sen, PP Potnuru, N Hernandez, C Goehl… - JAMA …, 2024 - jamanetwork.com
Importance Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is rapidly increasing in
the US, driven by its expanded approval for weight management in addition to …

[HTML][HTML] The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease

H Du, X Meng, Y Yao, J Xu - Frontiers in Endocrinology, 2022 - frontiersin.org
Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD) and both
have the same pathogenesis (eg, insulin resistance), drugs used to treat T2DM have been …

[HTML][HTML] GLP-1 receptor agonists in neurodegeneration: neurovascular unit in the spotlight

G Monti, D Gomes Moreira, M Richner, HAM Mutsaers… - Cells, 2022 - mdpi.com
Defects in brain energy metabolism and proteopathic stress are implicated in age-related
degenerative neuronopathies, exemplified by Alzheimer's disease (AD) and Parkinson's …

[HTML][HTML] The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health—A Narrative Review

M Hachuła, M Kosowski, K Zielańska, M Basiak… - International journal of …, 2023 - mdpi.com
Obesity, defined as body mass index (BMI)≥ 30 kg/m2, is one of the most important public
health problems. Over one billion people are obese, including 650 million adults, which is …

[HTML][HTML] Mitophagy: A potential therapeutic target for insulin resistance

P Ning, X Jiang, J Yang, J Zhang, F Yang… - Frontiers in …, 2022 - frontiersin.org
Glucose and lipid metabolism disorders caused by insulin resistance (IR) can lead to
metabolic disorders such as diabetes, obesity, and the metabolic syndrome. Early and …